We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




CT Software Receives Approval for Quantitative Bone Densitometry Technology

By MedImaging International staff writers
Posted on 28 Oct 2014
Print article
New computed tomography (CT) scanner software has received 510(k) clearance from the US Food and Drug Administration (FDA) to market asynchronous quantitative CT (QCT) calibration technology for CT-based bone mineral density measurement.

Mindways’ (Austin, TX, USA) latest QCT software advance makes it possible to evaluate bone mineral density (BMD) using QCT without the necessity to scan a calibration phantom together with the patient. This mean easier QCT workflow; but, more notably, now any non-intravenous (IV)-contrast abdominal or pelvic CT scan ordered for another reason can be used for additional bone density measurement with no further patient radiation exposure or time.

Mindways’ VP of business development, Alan Brett, PhD, said, “We are very excited about getting this innovative technology into healthcare practice. Because there is a great deal of overlap between patients getting a CT scan and those at risk of bone loss and consequent fragility fractures, the dual-use of CT scans provides for a very efficient method of screening for low bone mass and early identification patients that would benefit from treatment. This is very important because of the catastrophic nature of osteoporotic hip fractures.”

The new technology works by using an earlier acquired calibration scan to transform a CT image into bone mineral density values. In addition to standard CT scans, a successful pilot study has focused on the practicability of a combined CT colonography (CTC) and osteoporosis evaluation screening program. Because patients undergoing CTC screening are typically over the age of 50, they will be at risk of low bone mass, which is a specific concern for postmenopausal women. The dual use of a CTC scan can offer these patients “no-dose” BMD testing without the need to plan a dual-energy X-ray absorptiometry (DXA) test.

The new technology can also offer retrospective analysis of previously acquired images, by interrogating a picture archiving and communication system (PACS) store for CT scans of appropriate patient groups. The new technology will be available sometime in the last quarter of 2014.

Mindways Software, Inc. develops QCT bone densitometry products for spine and hip bone density measurements. The QCT Pro uses QCT images to derive DXA-like to obtain hip BMD measurements and volumetric spine BMD measurements. QCT Pro hip BMD measurements are interpreted in the same manner as DXA and are included in the World Health Organization (WHO; Geneva, Switzerland) FRAX online fracture risk calculator, whereas spine measurements provide excellent sensitivity to short-term bone density changes. QCT Pro is fast, easy to use, and provides the same clinical utility as DXA at less cost.

Related Links:

Mindways


X-Ray Illuminator
X-Ray Viewbox Illuminators
40/80-Slice CT System
uCT 528
New
Cylindrical Water Scanning System
SunSCAN 3D
Ultrasonic Pocket Doppler
SD1

Print article

Channels

Radiography

view channel
Image: The new machine algorithm can identify cardiovascular risk at the click of a button (Photo courtesy of Adobe Stock)

Machine Learning Algorithm Identifies Cardiovascular Risk from Routine Bone Density Scans

A new study published in the Journal of Bone and Mineral Research reveals that an automated machine learning program can predict the risk of cardiovascular events and falls or fractures by analyzing bone... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.